23andMe eyes Big Pharma for future growth

Mountain View, CA-based 23andMe is moving beyond its roots as a provider of consumer genetic tests, reports Xconomy's Luke Timmerman. The company has been targeting a new customer base, drug companies, which can tap the firm's database of 75,000 people for research purposes. "We still give people access to their genetic information," 23andMe CEO Anne Wojcicki said during a May 15 talk at a conference in Seattle. "But a lot more than that, we are really a research company." Story

Sponsored By Paraza Pharma

Choosing the Right Pre-Clinical Collaborative Research Organization (CRO)

Learn about the key factors that are essential to creating a collaborative and productive working relationship to advance pre-clinical drug discovery programs.